EMERALD: Updated Phase 3 Results by Duration of Prior CDK4/6i Treatment
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022. Oral Presentation
ELEVATE: A Phase 1b/2 Umbrella Study Evaluating Elacestrant in Various Combinations
ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating elacestrant in Various Combinations in Women and Men with Metastatic Breast Cancer (mBC). SABCS 2022. Poster
EMERALD: Phase 3 Subgroup Analysis
Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard of Care Endocrine Monotherapy for ER+/HER2- Advanced/Metastatic Breast Cancer: Subgroup Analysis from EMERALD. ESMO 2022. Poster
EMERALD: Subgroup Analysis of patients with no prior chemotherapy
EMERALD: Subgroup analysis of patients with no prior chemotherapy in a phase 3 trial evaluating elacestrant versus investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC). ASCO 2022. Poster
EMERALD: Phase 3 Results in ER+/HER2- advanced/metastatic breast cancer (mBC)
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on priorendocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. SABCS 2021. Oral Presentation
Phase 1: Final Analysis of ELACESTRANT in ER+/HER2- Advanced Breast Cancer
Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. SABCS 2019. Poster